adriforant   Click here for help

GtoPdb Ligand ID: 8985

Synonyms: PF 3893787 | PF-03893787 | ZPL-389 | ZPL-3893787 | ZPL389 | ZPL3893787
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Adriforant (ZPL-3893787) was a clinical stage immunomodulatory compound being developed by Ziarco Pharma (a Novartis subsidiary). Mechanistically it is a selective histamine H4 receptor antagonist. Novartis announced in their second-quarter financial report of 2020, that they were terminating the adriforant development programme.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 79.1
Molecular weight 262.19
XLogP 1.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CNC1CCN(C1)c1cc(NCC2CC2)nc(n1)N
Isomeric SMILES CN[C@@H]1CCN(C1)c1cc(NCC2CC2)nc(n1)N
InChI InChI=1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
InChI Key ISBHYKVAFKTATD-SNVBAGLBSA-N
No information available.
Summary of Clinical Use Click here for help
ZPL-3893787 reached Phase 2 clinical trial for evaluation as an antiinflammatory agent in patients with plaque psoriasis (see NCT02618616), and a Phase 1 in atopic dermatitis has been completed. Although the compound was better than placebo at reducing eczema symptoms such as inflammation in a phase 2a study for moderate-severe atopic dermatitis, it failed to meet an itch-related endpoint. Novartis terminated their ZPL-3893787 programme in mid-2020.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Allergic inflammation is reported to be augmented via histamine H4 receptor activation [1]. In light of this H4 receptor antagonists would be expected to inhibit this effect,
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02618616 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis Phase 2 Interventional Ziarco Pharma Ltd